Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;40(12):1265-1267.
doi: 10.1007/s40273-022-01213-y. Epub 2022 Nov 11.

Response to Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia"

Marjanne A Piena  1 , Natalie Houwing  2 , Carla W Kraan  2 , Xiaofeng Wang  3 , Heidi Waters  3 , Craig Bennison  4
Affiliations
Comment

Response to Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia"

Marjanne A Piena et al. Pharmacoeconomics. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

MP, CB, NH, and CK were paid consultants to Otsuka with regard to the development of this response letter. HW and XW are employees of Otsuka. MP, NH, CB, CK, HW, and XW have no other conflicts of interest to report. The authors disclose all financial or other relationships and all sources of financial support for this letter.

Comment on

References

    1. Rege B, et al. Comment on “an integrated pharmacokinetic-pharmacodynamic-pharmacoeconomic modeling method to evaluate treatments for adults with schizophrenia”. Pharmacoeconomics. 2022 doi: 10.1007/s40273-022-01200-3. - DOI - PMC - PubMed
    1. Piena MA, et al. An integrated pharmacokinetic-pharmacodynamic-pharmacoeconomic modeling method to evaluate treatments for adults with schizophrenia. Pharmacoeconomics. 2022;40:121–131. doi: 10.1007/s40273-021-01077-8. - DOI - PMC - PubMed
    1. Hard ML, et al. Pharmacokinetic profile of a 2-month dose regimen of aripiprazole lauroxil: a phase I study and a population pharmacokinetic model. CNS Drugs. 2017;31:617–624. doi: 10.1007/s40263-017-0447-7. - DOI - PMC - PubMed
    1. Wang X, et al. Population pharmacokinetic modeling and exposure-response analysis for aripiprazole once monthly in subjects with schizophrenia. Clin Pharmacol Drug Dev. 2022;11:150–164. doi: 10.1002/cpdd.1022. - DOI - PMC - PubMed
    1. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24:192–208. doi: 10.1097/01.jcp.0000117422.05703.ae. - DOI - PubMed